Sacituzumab govitecan

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946) . Sacituzumab govitecan shows anticancer activity[1].

Product Specifications

CAS Number

[1491917-83-9]

Product Name Alternative

IMMU-132

UNSPSC

12352203

Hazard Statement

H341, H360, H373

Target

Antibody-Drug Conjugates (ADCs) ; TROP2

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sacituzumab-govitecan.html

Purity

99.13

Solubility

H2O : 25 mg/mL (ultrasonic)

Smiles

[Sacituzumabgovitecan]

Molecular Weight

160000 (average)

Precautions

H341, H360, H373

References & Citations

[1]Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26 (5) :919-31. |[2]Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11 (10) :942]. Oncotarget. 2015;6 (26) :22496-22512. |[3]Cardillo TM, et al., Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26 (5) :919-31.